We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coronavirus Vaccine Development Puts These Stocks in Focus
Read MoreHide Full Article
Biotech firms and drugmakers across the globe are pumping in billions of dollars to develop a vaccine as the only resort to wipe out the deadly coronavirus but there is no sign of it yet.
However, a few companies have made substantial progress in the race to develop a vaccine. On Jul 27, Moderna, Inc. (MRNA - Free Report) launched the phase 3 trial of its vaccine candidate on thousands of volunteers. Separately, Pfizer, Inc. (PFE - Free Report) also advanced into its final-stage trials. This has once again raised hopes of a COVID-19 vaccine by the end of this year, which even some drugmakers consider possible.
Vaccine Hopes Rise Again
Moderna and Pfizer launched two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Jul 27. The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration’s effort to ramp up development of a coronavirus vaccine.
Moderna’s randomized, placebo-controlled trial is expected to include approximately 30,000 participants in the United States, testing an mRNA-1273 dosage of 100 µg. The primary endpoint will be the prevention of symptomatic COVID-19 disease. Moderna is working closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the phase 3 COVE study under the auspices of Operation Warp Speed.
The Pfizer vaccine study is being conducted in the United States and elsewhere. Like Moderna, Pfizer also aims to recruit 30,000 volunteers for the trial. Pfizer already has an agreement to sell 100 million doses of its vaccine to the U.S. government and give it the option to buy 500 million more.
Vaccine Race Heats Up
Although treatment for COVID-19 is yet to be found, a large number of drugmakers and biotech companies have made remarkable progress in developing a vaccine over the past couple of months. Also, some have started ramping up production of their vaccine candidates, anticipating huge demand if they prove successful.
Earlier this month, Dr. Anthony Fauci, United States’ leading infectious diseases doctor, said on Jul 6 that the nation will get to know by the end of this year whether a coronavirus vaccine is safe and effective. He had also assured that a vaccine will be available as soon as the clinical trials are complete, giving a boost to the confidence of millions.
Stocks in Focus
Moderna has been one of the frontrunners in the COVID-19 vaccine race. The company’s vaccine candidate mRNA-1273 is a molecule that genetically encodes a set of instructions based on which cells make proteins and send them to various parts of the body. Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in the early-stage study. Its shares have gained 30.4% in the past 30 days. Moderna has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer joined forces with German biotech giant BioNTech (BNTX - Free Report) to develop a vaccine for coronavirus. The 360 patients in the United States trial started to receive the first doses of the four vaccine candidates included in the study as of May 5. Dosing in 200 participants in the German trial began on Apr 23. The company has now entered its phase 2/3 safety and efficacy clinical study on 30,000 subjects. The candidate so far has shown promise and the U.S. government has also placed an initial order of 100 million doses for $1.95 billion to secure 500 million additional doses of the vaccine. Pfizer’s shares have advanced 17.2% in the past month. The Zacks Consensus Estimate for current-year earnings has improved 0.7% over the past 60 days. Pfizer carries a Zacks Rank #3 (Hold).
Gilead Sciences, Inc. (GILD - Free Report) in May received an emergency-use authorization from the FDA based on preliminary results from two clinical trials: one conducted by the NIAID and the other by Gilead. The company’s expected earnings growth rate for next year is 4.2%. The Zacks Consensus Estimate for current-year earnings has improved 3.9% over the past 30 days. Shares of the company have gained 14.7% year to date. Gilead has a Zacks Rank #3.
Amgen, Inc. (AMGN - Free Report) , one of the biggest biotech companies in the world, collaborated with Adaptive, Inc. (ADPT) in April to work on antibodies that can be used to prevent or treat COVID-19. Amgen also plans to test Otezla as a COVID-19 therapy treating respiratory distress in late-stage patients in the coming days.
Amgen’s expected earnings growth rate for the current year is 5.2%. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the past 60 days.
Dynavax Technologies Corporation (DVAX - Free Report) is developing a vaccine candidate SCB-2019 with GlaxoSmithKline plc (GSK - Free Report) which is in its phase 1 clinical trials. The vaccine is made up of S-Trimer protein that resembles the coronavirus spike protein and hence triggers the immune system to produce antibodies. Last week, Dynavax partnered with Taiwan-based Medigen Vaccine Biologics to develop an adjuvanted Covid-19 vaccine candidate.
The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.Dynavax’sshares have rallied 140.1% in the past three months. Dynavax has a Zacks Rank #3.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Coronavirus Vaccine Development Puts These Stocks in Focus
Biotech firms and drugmakers across the globe are pumping in billions of dollars to develop a vaccine as the only resort to wipe out the deadly coronavirus but there is no sign of it yet.
However, a few companies have made substantial progress in the race to develop a vaccine. On Jul 27, Moderna, Inc. (MRNA - Free Report) launched the phase 3 trial of its vaccine candidate on thousands of volunteers. Separately, Pfizer, Inc. (PFE - Free Report) also advanced into its final-stage trials. This has once again raised hopes of a COVID-19 vaccine by the end of this year, which even some drugmakers consider possible.
Vaccine Hopes Rise Again
Moderna and Pfizer launched two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Jul 27. The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration’s effort to ramp up development of a coronavirus vaccine.
Moderna’s randomized, placebo-controlled trial is expected to include approximately 30,000 participants in the United States, testing an mRNA-1273 dosage of 100 µg. The primary endpoint will be the prevention of symptomatic COVID-19 disease. Moderna is working closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the phase 3 COVE study under the auspices of Operation Warp Speed.
The Pfizer vaccine study is being conducted in the United States and elsewhere. Like Moderna, Pfizer also aims to recruit 30,000 volunteers for the trial. Pfizer already has an agreement to sell 100 million doses of its vaccine to the U.S. government and give it the option to buy 500 million more.
Vaccine Race Heats Up
Although treatment for COVID-19 is yet to be found, a large number of drugmakers and biotech companies have made remarkable progress in developing a vaccine over the past couple of months. Also, some have started ramping up production of their vaccine candidates, anticipating huge demand if they prove successful.
Earlier this month, Dr. Anthony Fauci, United States’ leading infectious diseases doctor, said on Jul 6 that the nation will get to know by the end of this year whether a coronavirus vaccine is safe and effective. He had also assured that a vaccine will be available as soon as the clinical trials are complete, giving a boost to the confidence of millions.
Stocks in Focus
Moderna has been one of the frontrunners in the COVID-19 vaccine race. The company’s vaccine candidate mRNA-1273 is a molecule that genetically encodes a set of instructions based on which cells make proteins and send them to various parts of the body. Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in the early-stage study. Its shares have gained 30.4% in the past 30 days. Moderna has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer joined forces with German biotech giant BioNTech (BNTX - Free Report) to develop a vaccine for coronavirus. The 360 patients in the United States trial started to receive the first doses of the four vaccine candidates included in the study as of May 5. Dosing in 200 participants in the German trial began on Apr 23. The company has now entered its phase 2/3 safety and efficacy clinical study on 30,000 subjects. The candidate so far has shown promise and the U.S. government has also placed an initial order of 100 million doses for $1.95 billion to secure 500 million additional doses of the vaccine. Pfizer’s shares have advanced 17.2% in the past month. The Zacks Consensus Estimate for current-year earnings has improved 0.7% over the past 60 days. Pfizer carries a Zacks Rank #3 (Hold).
Gilead Sciences, Inc. (GILD - Free Report) in May received an emergency-use authorization from the FDA based on preliminary results from two clinical trials: one conducted by the NIAID and the other by Gilead. The company’s expected earnings growth rate for next year is 4.2%. The Zacks Consensus Estimate for current-year earnings has improved 3.9% over the past 30 days. Shares of the company have gained 14.7% year to date. Gilead has a Zacks Rank #3.
Amgen, Inc. (AMGN - Free Report) , one of the biggest biotech companies in the world, collaborated with Adaptive, Inc. (ADPT) in April to work on antibodies that can be used to prevent or treat COVID-19. Amgen also plans to test Otezla as a COVID-19 therapy treating respiratory distress in late-stage patients in the coming days.
Amgen’s expected earnings growth rate for the current year is 5.2%. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the past 60 days.
Dynavax Technologies Corporation (DVAX - Free Report) is developing a vaccine candidate SCB-2019 with GlaxoSmithKline plc (GSK - Free Report) which is in its phase 1 clinical trials. The vaccine is made up of S-Trimer protein that resembles the coronavirus spike protein and hence triggers the immune system to produce antibodies. Last week, Dynavax partnered with Taiwan-based Medigen Vaccine Biologics to develop an adjuvanted Covid-19 vaccine candidate.
The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.Dynavax’sshares have rallied 140.1% in the past three months. Dynavax has a Zacks Rank #3.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>